Approved HIV Drugs
Approved HIV Drugs
EACS 2013: GSK1265744 Rapidly Suppresses HIV, Appears Safe At Selected Dose
- Details
- Category: Approved HIV Drugs
- Published on Saturday, 19 October 2013 00:00
- Written by Liz Highleyman
The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral activity and good tolerability for treatment-naive patients in the LATTE study, according to a report at the 14th European AIDS Conference this week in Brussels.
ICAAC 2013: Single-tablet Regimen Improves ART Adherence and Reduces Hospitalization
- Details
- Category: Approved HIV Drugs
- Published on Monday, 23 September 2013 00:00
- Written by Liz Highleyman
Antiretroviral treatment that requires only a single tablet taken once-daily were associated with better viral suppression, higher adherence, and lower likelihood of hospitalization, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver.
FDA Approves ViiV HIV Integrase Inhibitor Dolutegravir (Tivicay)
- Details
- Category: HIV Treatment
- Published on Monday, 12 August 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) today (August 12, 2013) approved the second HIV integrase inhibitor, dolutegravir, which will be marketed under the brand name Tivicay by ViiV Healthcare. Phase 3 studies showed that dolutegravir works as well as raltegravir (Isentress) or Atripla and is generally safe and well-tolerated.
ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups
- Details
- Category: Approved HIV Drugs
- Published on Monday, 16 September 2013 00:00
- Written by Liz Highleyman
The new integrase inhibitor dolutegravir (Tivicay) worked better than boosted darunavir for people starting HIV treatment for the first time, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver. Another study found that dolutegravir worked well across sex, race/ethnicity, and age groups.
IAS 2013: Raltegravir/Etravirine Dual Regimen Maintains Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 07 August 2013 00:00
- Written by Liz Highleyman
A regimen of raltegravir (Isentress) plus etravirine (Intelence) without NRTIs or protease inhibitors was able to keep HIV in check after switching from a standard regimen if patients did not have pre-existing NNRTI resistance, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
Web Design and Development by